latest news releases from the newsroom
Skandia -- Annual Report 2003
STOCKHOLM, Sweden, March 29, 2004 (PRIMEZONE) -- Today Skandia is publishing its 2003 Annual Report, both in Swedish and in English, on the Internet. The printed versions will be distributed shortly.
Antisoma plc Announces Findings Presented at AACR
LONDON, UK, March 29, 2004 (PRIMEZONE) -- Antisoma plc, the biopharmaceutical company specialising in the development of novel anti-cancer drugs, announces the presentation of promising new data from five of its oncology programmes at the American Association of Cancer Research meeting in Orlando, USA.
Volvo signs Engine Cooperation Frame Agreement Covering Engine Manufacture in China
GOTEBORG, Sweden, March 28, 2004 (PRIMEZONE) -- Volvo CEO Leif Johansson signed a Engine Cooperation Frame Agreement today in Beijing with the truck manufacturers China National Heavy Truck Corporation (CNHTC), and First Automotive Works (FAW) covering the establishment of a jointly owned engine plant in China. The plant will manufacture complete engines for Volvo's various business areas in China and for CNHTC's and FAW's trucks.
BioGentech Receives FDA Approval to Begin Phase III Clinical Trials
IRVINE, Calif., March 26, 2004 (PRIMEZONE) -- BioGentech Corp. (OTCBB:BGTH), a pharmaceutical company specializing in over-the-counter anti-allergy medications, announced today the Division of Pulmonary and Allergy Drug Products at the US Food and Drug Administration (FDA) has completed its review of, and has approved the Company to proceed with, Phase III clinical trials for its new allergy drug Prehistin(tm). Based upon this review and approval, BioGentech has initiated Phase III clinical trials to study the ability of Prehistin to mitigate the symptoms of seasonal allergies (seasonal allergic rhinitis). Prehistin is a sub-lingual lozenge requiring no physician visits or injections. A successful outcome to these Phase III trials would open the door for Prehistin to become the first-ever over-the-counter drug whose action would reduce or potentially eliminate the symptoms of season allergies, as opposed to the current paradigm of attacking such symptoms through the use of antihistimines.